Seven Fleet Capital Management LP Invests $1.37 Million in Dyne Therapeutics, Inc. $DYN

Seven Fleet Capital Management LP acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 70,180 shares of the company’s stock, valued at approximately $1,373,000. Dyne Therapeutics accounts for about 1.0% of Seven Fleet Capital Management LP’s portfolio, making the stock its 15th largest holding.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Strs Ohio bought a new position in Dyne Therapeutics in the 4th quarter worth $51,000. Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics during the fourth quarter valued at about $84,000. Steward Partners Investment Advisory LLC grew its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after buying an additional 1,440 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new stake in Dyne Therapeutics in the fourth quarter worth about $204,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Trading Up 3.1%

Shares of DYN stock opened at $19.80 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The stock has a fifty day simple moving average of $18.30 and a two-hundred day simple moving average of $18.09. The firm has a market capitalization of $3.27 billion, a PE ratio of -6.15 and a beta of 1.09. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the previous year, the company earned ($1.05) earnings per share. On average, analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CFO Erick Lucera sold 1,448 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $26,585.28. Following the sale, the chief financial officer owned 123,925 shares of the company’s stock, valued at approximately $2,275,263. This trade represents a 1.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 83,219 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total value of $1,512,921.42. Following the completion of the transaction, the director directly owned 7,962 shares in the company, valued at approximately $144,749.16. This represents a 91.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have purchased 9,000 shares of company stock worth $156,800 and have sold 1,559,462 shares worth $29,814,746. Company insiders own 9.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on DYN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Sanford C. Bernstein increased their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 15th. Morgan Stanley decreased their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.85.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.